MedPanel asked 100 rare disease treaters in the US and the UK if pharmaceutical companies should be involved in rare disease patient advocacy groups.
A little over half of the physicians surveyed felt pharma should play a role in supporting rare disease community.
What do you think? Does pharma have a role? What should that role be?